El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

718037.pdf (489.91 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2021-11

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/199602

Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma.

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/hep.32023

Resum

Background and aims: Lenvatinib is an effective drug in advanced HCC. Its combination with the anti-PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results in phase Ib and is currently being tested in phase III trials. Here, we aimed to explore the molecular and immunomodulatory effects of lenvatinib alone or in combination with anti-PD1. Approach and results: We generated three syngeneic models of HCC in C57BL/6J mice (subcutaneous and orthotopic) and randomized animals to receive placebo, lenvatinib, anti-PD1, or combination treatment. Flow cytometry, transcriptomic, and immunohistochemistry analyses were performed in tumor and blood samples. A gene signature, capturing molecular features associated with the combination therapy, was used to identify a subset of candidates in a cohort of 228 HCC patients who might respond beyond what is expected for monotherapies. In mice, the combination treatment resulted in tumor regression and shorter time to response compared to monotherapies (P < 0.001). Single-agent anti-PD1 induced dendritic and T-cell infiltrates, and lenvatinib reduced the regulatory T cell (Treg) proportion. However, only the combination treatment significantly inhibited immune suppressive signaling, which was associated with the TGFß pathway and induced an immune-active microenvironment (P < 0.05 vs. other therapies). Based on immune-related genomic profiles in human HCC, 22% of patients were identified as potential responders beyond single-agent therapies, with tumors characterized by Treg cell infiltrates, low inflammatory signaling, and VEGFR pathway activation. Conclusions: Lenvatinib plus anti-PD1 exerted unique immunomodulatory effects through activation of immune pathways, reduction of Treg cell infiltrate, and inhibition of TGFß signaling. A gene signature enabled the identification of ~20% of human HCCs that, although nonresponding to single agents, could benefit from the proposed combination.

Matèries

Càncer de fetge, Inhibidors enzimàtics, Vasos sanguinis, Proteïnes, Mort cel·lular, Immunoregulació

Matèries (anglès)

Liver cancer, Enzyme inhibitors, Blood vessels, Proteins, Cell death, Immunoregulation

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

TORRENS, Laura, MONTIRONI, Carla, PUIGVEHÍ, Marc, MESROPIAN, Agavni, LESLIE, Jack, HABER, Philipp k., MAEDA, Miho, BALASEVICIUTE, Ugne, WILLOUGHBY, Catherine e., ABRIL FORNAGUERA, Jordi, PIQUÉ GILI, Marta, TORRES MARTÍN, Miguel, PEIX, Judit, GEH, Daniel, RAMON GIL, Erik, SABERI, Behnam, FRIEDMAN, Scott l., MANN, Derek a., SIA, Daniela, LLOVET I BAYER, Josep maria. Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma.. _Hepatology_. 2021. Vol. 74, núm. 5, pàgs. 2652-2669. [consulta: 31 de desembre de 2025]. ISSN: 0270-9139. [Disponible a: https://hdl.handle.net/2445/199602]

Exportar metadades

JSON - METS

Compartir registre